ZOLL Medical Corporation LifeVest Wearable Defibrillator Reduces Total Mortality after Cardiac Revascularization

Published: Nov 15, 2011

AHA Scientific Sessions 2011

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation (NASDAQ GS: ZOLL), a manufacturer of medical devices and related software solutions, announced that a study demonstrating a reduction in total mortality after cardiac revascularization in patients prescribed a LifeVest® Wearable Defibrillator was presented at the American Heart Association’s Scientific Sessions 2011 in Orlando today.

Back to news